Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brown fat may hold key to weight loss drug response

NCT ID NCT07621640

Knowledge-focused Sponsor: Hallym University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study looks at whether brown adipose tissue (brown fat), which burns energy as heat, can predict how well people with obesity respond to the weight loss drug semaglutide (Wegovy). Eighty adults starting semaglutide will have PET/CT scans before and after 24 weeks of treatment, using a cooling vest to activate brown fat. Researchers will compare brown fat activity with weight loss and metabolic changes to see if it can serve as a personalized treatment guide.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Semaglutide (Wegovy)
What this could lead to
If successful, this could help doctors predict who will benefit most from semaglutide, leading to more personalized obesity treatment.
What could go wrong
This is an observational study, not a treatment trial. It may find no link between brown fat and weight loss, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Feb 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 20-70 years at the time of enrollment 2. Initiating semaglutide (Wegovy) treatment for obesity (newly starting treatment) 3. BMI ≥ 27 kg/m² with at least one weight-related comorbidity: * Hypertension (SBP ≥130 or DBP ≥80 mmHg, or on antihypertensive medication) * Dyslipidemia (LDL-C ≥130, TG ≥150, or low HDL-C, or on lipid-lowering medication) * Non-alcoholic fatty liver disease (NAFLD/MASLD, confirmed by imaging or ALT/AST ≥1.5× ULN) * Obstructive sleep apnea (AHI ≥5/hr or clinically diagnosed) * Established cardiovascular disease (CAD, stroke, PAD) * Obesity-related osteoarthritis of knee or hip with functional impairment OR BMI ≥ 30 kg/m² (regardless of comorbidity) 4. Ability and willingness to provide written informed consent Exclusion Criteria: 1. Diagnosis of type 1 or type 2 diabetes mellitus 2. History of neck surgery or radiation therapy to the neck 3. Use of anti-obesity medications within 1 month prior to enrollment, or current use of beta-adrenergic blocking agents 4. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) 5. Active malignancy, severe renal disease (eGFR \<30 mL/min/1.73m²), severe hepatic disease, or other severe endocrine disorders 6. Pregnancy or breastfeeding 7. Severe psychiatric illness or cognitive impairment precluding informed consent 8. Contraindication to MRI (pacemaker, cochlear implant, non-MRI-compatible implants) 9. Severe claustrophobia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brown adipose tissue are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brown adipose tissue Metabolic syndrome Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hallym University Dongtan Sacred Heart Hospital

    Hwaseong-si, Gyeonggi-do, 18450, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.